Author： Kaski Juan-Carlos
Publisher： Springer Publishing Company
ISSN： 0920-3206
Source： Cardiovascular Drugs and Therapy, Vol.25, Iss.2, 2011-04, pp. : 187-188
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Rosiglitazone and MI risk - will we ever know the answer?
Inpharma, Vol. 1, Iss. 1594, 2007-01 ,pp. :
Access to resources
Recommend
Quantifying Adverse Drug Events: Are Systematic Reviews the Answer?
By Mahyar Etminan Bruce Carleton Paula A. Rochon
Drug Safety, Vol. 27, Iss. 11, 2004-01 ,pp. :
Inpharma, Vol. 1, Iss. 1335, 2002-01 ,pp. :
Pharmacotherapy or Surgery as Primary Treatment for Acromegaly?
By Ferone D.
Drugs & Aging, Vol. 17, Iss. 2, 2000-08 ,pp. :